Healthcare >> CEO Interviews >> December 2, 1999
HARRY PENNER, JR. is President, Chief Executive Officer, and Vice
Chairman of Neurogen Corporation in Branford, CT. Since joining Neurogen
in 1993, he has led the company into multiple clinical trials, to
dramatic portfolio growth, to important corporate alliances with Pfizer,
Schering-Plough, Wyeth-Ayerst, and to a $46 million secondary public
offering. Under Mr. Penner's leadership Neurogen has become one of the
more broadly based and better financed companies in the biotechnology
sector. Mr. Penner serves on the Boards of Directors of Neurogen and
Avant Immunotherapeutics, Inc., both of which are public companies. He
also serves on the Boards of Directors of PRA International, Inc., a
privately held clinical research organization, and Genaissance, Inc., a
privately held pharmacogenomics company. Mr. Penner currently serves as
Co-Chairman of CURE, Connecticut's Bioscience Cluster, as a member of
the Board of Governors of Higher Education in Connecticut, and as a
member of the Boards of Directors of the Connecticut Business and
Industry Association (CBIA), the Connecticut Technology Council (CTC),
and the Biotechnology Industry Organization (BIO). Mr. Penner was
previously an Executive Vice President of Novo Nordisk A/S and holds
academic degrees from the University of Virginia (BA), Fordham
University (JD), and New York University (LLM). Profile
believe will be the significant trends, developments or changes that you
anticipate in your sector of the market over the
